secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001867096-25-000156
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Q3 product revenue $74M (+40% YoY); raises FY2025 guidance to $285-290M
-----------------------------------------------------------------------------

- Total product revenue $74.1M, up 40% YoY; total revenue $74.4M (+37% YoY).
- Recorlev revenue $37.0M (+109% YoY); Gvoke $25.2M (+10%); Keveyis $11.9M (-2%).
- Net income $0.6M vs net loss $15.7M in Q3 2024; adjusted EBITDA $17.4M.
- FY2025 total revenue guidance raised to $285-290M from $280-290M, implying ~42% growth at midpoint.
- CEO cites record quarter driven by increased patient demand across all three products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000156/0001867096-25-000156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000156/xers-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001867096-25-000156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer